News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
300,115 Results
Type
Article (19866)
Company Profile (166)
Press Release (280077)
Multimedia
Podcasts (88)
Webinars (3)
Section
Business (74368)
Career Advice (136)
Deals (12701)
Drug Delivery (67)
Drug Development (56589)
Employer Resources (31)
FDA (9083)
Job Trends (6161)
News (148713)
Policy (12255)
Tag
2027 Biotech Bay Standard (2)
2027 Genetown Elite (1)
2027 Pharm Country Standard (3)
Academia (1106)
Academic (1)
Accelerated approval (31)
Adcomms (25)
Allergies (74)
Alliances (20789)
ALS (137)
Alzheimer's disease (1190)
Antibody-drug conjugate (ADC) (285)
Approvals (9293)
Artificial intelligence (272)
Autoimmune disease (135)
Automation (17)
Bankruptcy (92)
Best Places to Work (5686)
BIOSECURE Act (13)
Biosimilars (106)
Biotechnology (120)
Bladder cancer (140)
Brain cancer (57)
Breast cancer (560)
Cancer (4139)
Cardiovascular disease (326)
Career advice (126)
Career pathing (4)
CAR-T (305)
CDC (9)
Celiac Disease (1)
Cell therapy (819)
Cervical cancer (18)
Clinical research (49949)
Collaboration (1286)
Company closure (2)
Compensation (600)
Complete response letters (51)
COVID-19 (1163)
CRISPR (89)
C-suite (542)
Cystic fibrosis (132)
Data (5096)
Denatured (11)
Depression (108)
Diabetes (373)
Diagnostics (1994)
Digital health (22)
Diversity (2)
Diversity, equity & inclusion (6)
Drug discovery (175)
Drug pricing (95)
Drug shortages (24)
Duchenne muscular dystrophy (213)
Earnings (30818)
Editorial (24)
Employer branding (6)
Employer resources (29)
Events (51012)
Executive appointments (578)
FDA (11320)
Fibrodysplasia Ossificans Progressiva (3)
Friedreich's ataxia (10)
Frontotemporal dementia (19)
Funding (974)
Gene editing (189)
Generative AI (23)
Gene therapy (669)
GLP-1 (788)
Government (1661)
Grass and pollen (1)
Guidances (214)
Healthcare (8648)
HIV (39)
Huntington's disease (42)
IgA nephropathy (75)
Immunology and inflammation (201)
Immuno-oncology (47)
Indications (80)
Infectious disease (1275)
Inflammatory bowel disease (148)
Inflation Reduction Act (5)
Influenza (39)
Intellectual property (163)
Interviews (22)
IPO (6983)
IRA (20)
Job creations (793)
Job search strategy (104)
JPM (46)
Kidney cancer (10)
Labor market (23)
Layoffs (266)
Leadership (5)
Legal (1424)
Liver cancer (65)
Longevity (11)
Lung cancer (573)
Lymphoma (362)
Machine learning (22)
Management (7)
Manufacturing (526)
MASH (141)
Medical device (4547)
Medtech (4566)
Mergers & acquisitions (6388)
Metabolic disorders (1012)
Multiple sclerosis (131)
NASH (14)
Neurodegenerative disease (267)
Neuropsychiatric disorders (77)
Neuroscience (2182)
Neurotech (1)
NextGen: Class of 2026 (2418)
Non-profit (1397)
Now hiring (14)
Obesity (487)
Opinion (133)
Ovarian cancer (140)
Pain (153)
Pancreatic cancer (179)
Parkinson's disease (243)
Partnered (16)
Patents (310)
Patient recruitment (396)
Peanut (37)
People (22787)
Pharmaceutical (34)
Pharmacy benefit managers (10)
Phase 1 (15557)
Phase 2 (22431)
Phase 3 (16869)
Pipeline (3793)
Policy (138)
Postmarket research (1607)
Preclinical (5980)
Press Release (64)
Prostate cancer (206)
Psychedelics (51)
Radiopharmaceuticals (222)
Rare diseases (769)
Real estate (1608)
Recruiting (14)
Regulatory (12307)
Reports (20)
Research institute (1320)
Resumes & cover letters (20)
Rett syndrome (26)
RNA editing (14)
RSV (30)
Schizophrenia (118)
Series A (174)
Series B (136)
Service/supplier (4)
Sickle cell disease (86)
Special edition (15)
Spinal muscular atrophy (137)
Sponsored (25)
Startups (1616)
Stomach cancer (15)
Supply chain (55)
Tariffs (39)
The Weekly (76)
Vaccines (382)
Venture capital (63)
Weight loss (308)
Women's health (34)
Worklife (1)
Date
Last 7 days (400)
Last 30 days (1300)
Last 365 days (20124)
2026 (1909)
2025 (20285)
2024 (22198)
2023 (23899)
2022 (28769)
2021 (30068)
2020 (25626)
2019 (19119)
2018 (14126)
2017 (15134)
2016 (13220)
2015 (15301)
2014 (10232)
2013 (7489)
2012 (7638)
2011 (7808)
2010 (7101)
Location
Africa (182)
Alabama (51)
Alaska (3)
Arizona (93)
Arkansas (5)
Asia (18611)
Australia (3203)
California (7269)
Canada (1664)
China (925)
Colorado (231)
Connecticut (340)
Delaware (233)
Europe (44178)
Florida (998)
Georgia (208)
Hawaii (2)
Idaho (22)
Illinois (455)
India (53)
Indiana (287)
Iowa (13)
Japan (325)
Kansas (58)
Kentucky (25)
Louisiana (13)
Maine (8)
Maryland (857)
Massachusetts (5727)
Michigan (92)
Minnesota (328)
Mississippi (2)
Missouri (97)
Montana (9)
Nebraska (3)
Nevada (68)
New Hampshire (34)
New Jersey (2104)
New Mexico (16)
New York (1936)
North Carolina (994)
North Dakota (9)
Northern California (3677)
Ohio (215)
Oklahoma (10)
Oregon (20)
Pennsylvania (1500)
Puerto Rico (5)
Rhode Island (22)
South America (238)
South Carolina (19)
Southern California (2721)
Tennessee (56)
Texas (1077)
United States (25638)
Utah (127)
Virginia (160)
Washington D.C. (38)
Washington State (667)
West Virginia (1)
Wisconsin (70)
300,115 Results for "pep therapy".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
INTENT Biologics Receives FDA Fast Track Designation for PEP Biologic™
January 8, 2026
·
4 min read
Press Releases
INTENT Biologics Receives FDA Agreement Granting a Full Waiver for its Pediatric Study Plan for PEP Biologic™ in Advanced Wound Care
January 22, 2026
·
3 min read
Press Releases
PEP-Therapy receives FDA Orphan Drug Designation for PEP-010 for treatment of Pancreatic Cancer
March 17, 2025
·
4 min read
Business
PEP-Therapy and Institut Curie Announce First Patients Dosed in Phase Ib Clinical Trial Evaluating PEP-010 in Ovarian and Pancreatic Cancers
PEP-Therapy, a clinical-stage biotechnology company developing first-in-class peptides as targeted therapies in oncology, and Institut Curie, France’s leading cancer center, announced the dosing of the first patients in a Phase Ib clinical trial evaluating PEP-Therapy’s lead candidate, PEP-010, based on highly encouraging Phase Ia results.
April 25, 2024
·
6 min read
Press Releases
Zonsen PepLib Biotech and Novartis Sign Worldwide License Agreement regarding Radioligand Therapy Asset
January 14, 2026
·
2 min read
Press Releases
Rion Aesthetics Supports Initiation of the First U.S. Investigator-Initiated Clinical Trial of Dermal Injections with PEP™ Exosomes
June 3, 2025
·
4 min read
Press Releases
Versant Ventures Unveils Pep2Tango Therapeutics Inc.
November 21, 2024
·
4 min read
Press Releases
RION Announces First Patient Enrolled in Phase 1b Clinical Study Evaluating Purified Exosome Product™ (PEP™) for Knee Osteoarthritis
March 12, 2025
·
3 min read
Rare diseases
FDA Unwraps ‘Plausible Mechanism Pathway’ for Personalized Therapies
The plausible mechanism pathway “could accelerate gene therapy/editing development,” analysts at William Blair said Thursday, while adding that additional clarity is needed.
November 13, 2025
·
3 min read
·
Tristan Manalac
Drug Development
RION Announces Initiation of Phase 2A Clinical Study for Purified Exosome Product™ (PEP™) in Diabetic Foot Ulcers
RION’s Phase 2A clinical trial focuses on evaluating the safety and efficacy of Platelet Exosome Product™ (PEP™) combined with TISSEEL fibrin sealant for treating Diabetic Foot Ulcers (DFU).
January 30, 2024
·
6 min read
1 of 30,012
Next
